SuperworthUsana Health Sciences EPS USNA
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jul 4, 2026
- −$1.21
- Latest quarter, Q2 FY26
- −$1.16
- −323% on a year earlier
- Fiscal year 2025
- $0.55
- −75% on the year before
Usana Health Sciences' earnings per share was −$1.21 over the twelve months to Jul 4, 2026, down 167% on a year earlier.
In its latest quarter, Q2 FY26, it was −$1.16, down 323% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $0.55 | −75% |
| FY2024 | $2.19 | −34% |
| FY2023 | $3.30 | −8% |
| FY2022 | $3.59 | −37% |
| FY2021 | $5.71 | −3% |
| FY2020 | $5.86 | +33% |
| FY2019 | $4.42 | −14% |
| FY2018 | $5.11 | +103% |
| FY2017 | $2.52 | −37% |
| FY2016 | $3.99 | +11% |
| FY2015 | $3.58 | +27% |
| FY2014 | $2.81 | +1% |
| FY2013 | $2.79 | +25% |
| FY2012 | $2.23 | +37% |
| FY2011 | $1.63 | +14% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.16 | −323% | −$1.21 | |
| Q1 FY26 | $0.41 | −16% | $0.47 | |
| Q4 FY25 | −$0.10 | −143% | $0.55 | |
| Q3 FY25 | −$0.36 | −164% | $0.88 | |
| Q2 FY25 | $0.52 | −4% | $1.80 | |
| Q1 FY25 | $0.49 | −43% | $1.82 | |
| Q4 FY24 | $0.23 | −74% | $2.19 | |
| Q3 FY24 | $0.56 | −5% | $2.83 | |
| Q2 FY24 | $0.54 | −39% | $2.86 | |
| Q1 FY24 | $0.86 | −9% | $3.21 | |
| Q4 FY23 | $0.87 | +32% | $3.30 | |
| Q3 FY23 | $0.59 | −24% | $3.09 |
Against its peers
Companies in Chemicals nearest Usana Health Sciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| USNAUsana Health Sciences | −$1.21 | −167% a year |
| NAGENiagen Bioscience | $0.18 | −14% a year |
| FTLFFitlife Brands | $0.62 | −23% a year |
| FTKFlotek Industries | $0.99 | +125% a year |
| CRONCronos | $0.20 | +300% a year |
| BTMDbiote | $0.10 | −89% a year |
| ROGRogers | $1.75 | |
| NGVTIngevity | $1.47 | |
| IOSPInnospec | $4.90 | +545% a year |
| Peer median | $0.81 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Usana Health Sciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.